PoPH的临床诊断是基于门静脉高压患者的血流动力学检测发现PAH，需排除导致肺动脉或肺静脉高压的其他因素。早期轻中度PoPH患者一般无明显症状和体征，随着病情进展，可出现呼吸困难或劳力性胸痛、晕厥、疲劳、咯血、心悸和全身肿胀等，症状均具有非特异性。

Pulmonary arterial hypertension (PAH) is one of five types of pulmonary hypertension. It happens when the blood vessels in your lungs narrow and scar so much that it’s hard for blood to move ...

Addressing sleep-related complaints may enhance symptomatic treatment and management of PAH. Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was ...

All blood vessels are specifically structured to perform their function. For example, a capillary is microscopically thin to allow gases to exchange, the arteries are tough and flexible to cope ...

ETHealthworld.com brings latest pulmonary arterial hypertension news, views and updates from all top sources for the Indian Health industry.

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...

KIRKLAND, QC, Nov. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR ® (sotatercept) for ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...